Short Interest in Immunic, Inc. (NASDAQ:IMUX) Decreases By 15.6%

Immunic, Inc. (NASDAQ:IMUX) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 3,800,000 shares, a decline of 15.6% from the October 31st total of 4,500,000 shares. Based on an average daily trading volume, of 803,700 shares, the days-to-cover ratio is currently 4.7 days.

Insider Buying and Selling at Immunic

In other news, Director Richard Alan Rudick acquired 87,300 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were bought at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the acquisition, the director now directly owns 87,300 shares in the company, valued at $100,395. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IMUX. Janus Henderson Group PLC acquired a new stake in shares of Immunic in the 1st quarter valued at about $9,266,000. Vanguard Group Inc. raised its stake in Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after buying an additional 1,703,047 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Jane Street Group LLC lifted its stake in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Immunic in the 3rd quarter valued at about $50,000. 51.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IMUX. B. Riley initiated coverage on shares of Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price for the company. Leerink Partners reissued an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a research report on Monday, September 9th. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Immunic currently has a consensus rating of “Buy” and a consensus price target of $11.80.

Immunic Stock Up 12.9 %

Shares of Immunic stock traded up $0.16 on Monday, hitting $1.40. 1,311,655 shares of the company’s stock traded hands, compared to its average volume of 627,521. The firm’s 50-day moving average is $1.34 and its 200 day moving average is $1.34. The stock has a market cap of $126.11 million, a P/E ratio of -1.14 and a beta of 1.89. Immunic has a 52-week low of $0.97 and a 52-week high of $2.11.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.